The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...

DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen ...

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program ...

Alkermes saw dose-dependent increases in sleep latency ranging from 18.4 minutes on 1mg to 34.0 minutes on 8mg. Sleep latency fell 1.4 minutes on placebo. Mizuho analysts took a positive view of ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Eledon Pharmaceuticals (ELDN – Research Report) and Legend ...

Alkermes PLC (NASDAQ:ALKS) is a fast-growing pharmaceutical company headquartered in Dublin, Ireland. Not only does the company have an extensive pipeline of product candidates being developed ...

NORTHAMPTON, MA / ACCESSWIRE / November 29, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility ReportWe understand the significant potential impacts that ...

Shareholders in Alkermes have quelled a challenge from Sarissa Capital, reelecting seven board members and rejecting three nominees from the activist investor, the Ireland-based drugmaker said ...

DUBLIN, April 26, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2023. "During the first quarter we made continued progress across our ...

Is Alkermes (ALKS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be a ...

Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.